[go: up one dir, main page]

MX2016001156A - Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion. - Google Patents

Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion.

Info

Publication number
MX2016001156A
MX2016001156A MX2016001156A MX2016001156A MX2016001156A MX 2016001156 A MX2016001156 A MX 2016001156A MX 2016001156 A MX2016001156 A MX 2016001156A MX 2016001156 A MX2016001156 A MX 2016001156A MX 2016001156 A MX2016001156 A MX 2016001156A
Authority
MX
Mexico
Prior art keywords
pyrazinamide
ethambutol
isoniazid
preparation
rifampicin
Prior art date
Application number
MX2016001156A
Other languages
English (en)
Inventor
Prasad Kum
Khullar Praveen
Kumar Amith
Madavan Bindu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51212860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016001156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2016001156A publication Critical patent/MX2016001156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un comprimido monocapa para uso en el tratamiento de la tuberculosis que comprende una mezcla de: gránulos que comprenden isoniazid, pirazinamida, etambutol o una sal farmacéuticamente aceptable de éste y al menos un aglutinante de granulación; rifampicina en forma de polvo; excipientes extragranulares, en el que todos los gránulos tienen un tamaño de partícula que es menor de 0,599 mm, preferiblemente menor de 0,5 mm, más preferiblemente menor de 0,422 mm, y a su proceso de preparación.
MX2016001156A 2013-07-26 2014-07-22 Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion. MX2016001156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3343CH2013 2013-07-26
PCT/EP2014/065763 WO2015011163A1 (en) 2013-07-26 2014-07-22 Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.

Publications (1)

Publication Number Publication Date
MX2016001156A true MX2016001156A (es) 2016-04-29

Family

ID=51212860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001156A MX2016001156A (es) 2013-07-26 2014-07-22 Composicion antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparacion.

Country Status (18)

Country Link
US (1) US9814711B2 (es)
EP (1) EP3024445B1 (es)
JP (1) JP2017501117A (es)
CN (1) CN105407874A (es)
AU (1) AU2014295100B2 (es)
CA (1) CA2918828A1 (es)
CL (1) CL2016000180A1 (es)
HK (1) HK1218721A1 (es)
IL (1) IL243370A0 (es)
MX (1) MX2016001156A (es)
MY (1) MY174007A (es)
PE (1) PE20160238A1 (es)
PH (1) PH12016500118A1 (es)
RU (1) RU2672879C2 (es)
SG (1) SG11201510699WA (es)
TW (1) TW201601716A (es)
WO (1) WO2015011163A1 (es)
ZA (1) ZA201600108B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694056C2 (ru) 2013-07-26 2019-07-09 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
LT3439655T (lt) * 2016-04-08 2021-07-12 Quretech Bio Ab Koncentruotų žiedų tiazolino-2-piridonai, jų gamybos būdai ir jų panaudojimas tuberkuliozės gydymui ir (arba) prevencijai
JP7233059B2 (ja) * 2017-10-05 2023-03-06 キュアテック バイオ アーベー 結核に対する薬剤と組み合わせた環融合型チアゾリノ２－ピリドン
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
CN108186638A (zh) * 2018-03-08 2018-06-22 重庆华邦制药有限公司 异烟肼的药物组合物
CN118984700A (zh) * 2021-12-07 2024-11-19 An2治疗公司 组合

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
RU2240795C9 (ru) * 2000-08-09 2005-09-27 Панацея Биотек Лимитед Фармацевтические композиции противотуберкулезных лекарственных средств и способ их изготовления
BR0116994A (pt) * 2001-04-27 2004-03-02 Lupin Ltd Um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (fdc) de quatro drogas antituberculose
RU2195937C1 (ru) * 2002-02-06 2003-01-10 НИИ молекулярной медицины ММА им. И.М.Сеченова Комбинированный противотуберкулезный препарат (ризобутол)
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
WO2005074937A1 (en) * 2004-02-04 2005-08-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of anti-tuberculosis drug
TWI368509B (en) 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
RU2012105674A (ru) 2009-07-31 2013-09-10 Кадила Фармасьютикалз Лтд. Фармацевтическая композиция изониазида
WO2012013756A2 (fr) * 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
RU2694056C2 (ru) 2013-07-26 2019-07-09 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
RU2682178C2 (ru) 2013-07-26 2019-03-15 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления

Also Published As

Publication number Publication date
EP3024445B1 (en) 2019-01-09
TW201601716A (zh) 2016-01-16
PE20160238A1 (es) 2016-05-05
HK1218721A1 (zh) 2017-03-10
US20160158226A1 (en) 2016-06-09
CL2016000180A1 (es) 2016-06-24
MY174007A (en) 2020-03-03
WO2015011163A1 (en) 2015-01-29
RU2672879C2 (ru) 2018-11-20
ZA201600108B (en) 2017-04-26
US9814711B2 (en) 2017-11-14
CN105407874A (zh) 2016-03-16
RU2016106336A3 (es) 2018-05-17
AU2014295100B2 (en) 2019-01-03
PH12016500118A1 (en) 2016-04-25
RU2016106336A (ru) 2017-08-31
CA2918828A1 (en) 2015-01-29
AU2014295100A1 (en) 2016-02-11
SG11201510699WA (en) 2016-01-28
JP2017501117A (ja) 2017-01-12
IL243370A0 (en) 2016-02-29
EP3024445A1 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
PH12016500118A1 (en) Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
PH12018501073A1 (en) Eif4-a-inhibiting compounds and methods related thereto
SA515361055B1 (ar) نواتج تكتل قابلة للاستنشاق من جسيمات حاملة مسامية وعقار بحجم الميكرون
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
MX2015013845A (es) Polvos secos de tiotropio.
MX2021001583A (es) Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MY179703A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
PH12016502272A1 (en) Ceritinib formulation
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2016006464A (es) Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
PH12017500323A1 (en) P38 map kinase inhibiting indanyl urea compounds
NZ724063A (en) Pyrazine derivatives having pharmaceutical activity
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
SG11201807106WA (en) Glycine particles
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
TN2013000015A1 (en) Dry powder formulation comprising a phosphodiesterase inhibitor